| Literature DB >> 28456385 |
Manar Aoun1, Paola Antonia Corsetto2, Guillaume Nugue3, Gigliola Montorfano2, Emilio Ciusani4, David Crouzier3, Penelope Hogarth5, Allison Gregory5, Susan Hayflick5, Giovanna Zorzi6, Angela Maria Rizzo7, Valeria Tiranti8.
Abstract
Pantothenate Kinase-Associated Neurodegeneration (PKAN) is a form of Neurodegeneration with Brain Iron Accumulation (NBIA) associated with mutations in the pantothenate kinase 2 gene (PANK2). The PANK2 catalyzes the first step of coenzyme A (CoA) biosynthesis, a pathway producing an essential cofactor that plays a key role in energy and lipid metabolism. The majority of PANK2 mutations reduces or abolishes the activity of the enzyme. In around 10% of cases with PKAN, the presence of deformed red blood cells with thorny protrusions in the circulation has been detected. Changes in membrane protein expression and assembly during erythropoiesis were previously explored in patients with PKAN. However, data on red blood cell membrane phospholipid organization are still missing in this disease. In this study, we performed lipidomic analysis on red blood cells from Italian patients affected by PKAN with a particular interest in membrane physico-chemical properties. We showed an increased number of small red blood cells together with membrane phospholipid alteration, particularly a significant increase in sphingomyelin (SM)/phosphatidylcholine (PC) and SM/phosphatidylethanolamine (PE) ratios, in subjects with PKAN. The membrane structural abnormalities were associated with membrane fluidity perturbation. These morphological and functional characteristics of red blood cells in patients with PKAN offer new possible tools in order to shed light on the pathogenesis of the disease and to possibly identify further biomarkers for clinical studies.Entities:
Keywords: Biomarkers; Erythrocytes; Membrane; Mitochondria; NBIA; Neurodegenerative diseases; Oxidized lipids; PKAN; Phospholipids
Mesh:
Substances:
Year: 2017 PMID: 28456385 DOI: 10.1016/j.ymgme.2017.04.006
Source DB: PubMed Journal: Mol Genet Metab ISSN: 1096-7192 Impact factor: 4.797